-

Mirum Pharmaceuticals to Participate at Four Upcoming Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the following conferences in February and March.

  • SVB Leerink 9th Annual Global Healthcare Conference
    • Location: New York, NY
    • Presentation date: Wednesday February 26, 2020
    • Presentation time: 9:30 a.m. ET
  • Cowen 40th Annual Healthcare Conference
    • Location: Boston, MA
    • Presentation date: Monday March 2, 2020
    • Presentation time: 2:10 p.m. ET
  • Raymond James 41st Annual Institutional Investors Conference
    • Location: Orlando, FL
    • Presentation date: Wednesday March 4, 2020
    • Presentation time: 9:15 a.m. ET

A live audio webcast and archive of the presentations outline above will be available at http://ir.mirumpharma.com

Additionally, the company will be participating the 32nd Annual ROTH Conference, and will be on a panel on Monday March 16 at 11:00 a.m. discussing Orphan Therapeutics.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.

Contacts

Media Contact:
Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi@canalecomm.com

Investor Contact:
Ian Clements, Ph.D.
650-667-4085
ir@mirumpharma.com

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Release Versions

Contacts

Media Contact:
Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi@canalecomm.com

Investor Contact:
Ian Clements, Ph.D.
650-667-4085
ir@mirumpharma.com

More News From Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026...
Back to Newsroom